title: Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.
abstract: Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes and lacks common therapeutic targets, including HER 2 and the estrogen and progesterone receptors. The clinicopathological heterogeneity of the disease and limited treatment options make clinical management particularly challenging. Here we present the results of a survey of Canadian clinical oncologists regarding treatment of TNBC, and review recent and ongoing clinical research in this area. Our survey results show that the majority of respondents use a combination of anthracyclines-taxanes as adjuvant therapy for early TNBC. For the first-line treatment of metastatic TNBC, most clinicians recommend taxanes, while single agent capecitabine and platinum-based therapies are more common for subsequent lines of therapy. Despite the ongoing development of novel targeted therapies, chemotherapy remains the mainstay of treatment for TNBC.
authors.affiliation: University of Toronto and Sunnybrook Health Sciences Centre, Toronto, ON.
authors.forename: S
authors.initials: S
authors.lastname: Verma
authors.forename: L
authors.initials: L
authors.lastname: Provencher
authors.forename: R
authors.initials: R
authors.lastname: Dent